| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8815801 | ABBVIE ENDOCRINE INC | Controlled release composition and method of producing the same |
Jun, 2022
(1 year, 3 months ago) | |
| US8921326 | ABBVIE ENDOCRINE INC | Sustained-release composition and method for producing the same |
Feb, 2031
(7 years from now) | |
Lupron Depot is owned by Abbvie Endocrine Inc.
Lupron Depot contains Leuprolide Acetate.
Lupron Depot has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Lupron Depot are:
- US8815801
Lupron Depot was authorised for market use on 22 December, 1995.
Lupron Depot is available in injectable;injection dosage forms.
Lupron Depot can be used as palliative treatment of prostate cancer.
The generics of Lupron Depot are possible to be released after 05 February, 2031.
Drugs and Companies using LEUPROLIDE ACETATE ingredient
Market Authorisation Date: 22 December, 1995
Treatment: Palliative treatment of prostate cancer
Dosage: INJECTABLE;INJECTION
LUPRON DEPOT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic